BPTH Key Statistics, Chart & Performance
The current stock price of BPTH is 0.21 USD. In the past month the price decreased by -74.39%. In the past year, price decreased by -96.41%.
BPTH Latest News, Press Relases and Analysis
BPTH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About BPTH
Company Profile
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The company is headquartered in Bellaire, Texas and currently employs 10 full-time employees. The company went IPO on 2006-01-11. The firm is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.
Company Info
BIO-PATH HOLDINGS INC
4710 Bellaire Boulevard, Suite 210
Bellaire TEXAS 77401 US
CEO: Peter H. Nielsen
Employees: 10
Phone: 18327421357
BIO-PATH HOLDINGS INC / BPTH FAQ
Can you describe the business of BIO-PATH HOLDINGS INC?
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The company is headquartered in Bellaire, Texas and currently employs 10 full-time employees. The company went IPO on 2006-01-11. The firm is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.
Can you provide the latest stock price for BIO-PATH HOLDINGS INC?
The current stock price of BPTH is 0.21 USD. The price decreased by -66.84% in the last trading session.
Does BPTH stock pay dividends?
BPTH does not pay a dividend.
What is the ChartMill rating of BIO-PATH HOLDINGS INC stock?
BPTH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the Price/Earnings (PE) ratio of BIO-PATH HOLDINGS INC (BPTH)?
BIO-PATH HOLDINGS INC (BPTH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-13.79).
What is the market capitalization of BPTH stock?
BIO-PATH HOLDINGS INC (BPTH) has a market capitalization of 905.10K USD. This makes BPTH a Nano Cap stock.
What is the outstanding short interest for BIO-PATH HOLDINGS INC?
The outstanding short interest for BIO-PATH HOLDINGS INC (BPTH) is 0.05% of its float.
BPTH Technical Analysis
BPTH Financial Highlights
Over the last trailing twelve months BPTH reported a non-GAAP Earnings per Share(EPS) of -13.79. The EPS increased by 66.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -354.57% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BPTH Forecast & Estimates
7 analysts have analysed BPTH and the average price target is 12.24 USD. This implies a price increase of 5728.57% is expected in the next year compared to the current price of 0.21.